Literature DB >> 25413735

Remission of rheumatoid arthritis and potential determinants: a national multi-center cross-sectional survey.

Guan-Ying Wang1, Sa-Li Zhang, Xiu-Ru Wang, Min Feng, Chun Li, Yuan An, Xiao-Feng Li, Li-Zhi Wang, Cai-Hong Wang, Yong-Fu Wang, Rong Yang, Hui-Ming Yan, Guo-Chun Wang, Xin Lu, Xia Liu, Ping Zhu, Li-Na Chen, Hong-Tao Jin, Jin-Ting Liu, Hui-Fang Guo, Hai-Ying Chen, Jian-Li Xie, Ping Wei, Jun-Xiang Wang, Xiang-Yuan Liu, Lin Sun, Liu-Fu Cui, Rong Shu, Bai-Lu Liu, Ping Yu, Zhuo-Li Zhang, Guang-Tao Li, Zhen-Bin Li, Jing Yang, Jun-Fang Li, Bin Jia, Feng-Xiao Zhang, Jie-Mei Tao, Jin-Ying Lin, Mei-Qiu Wei, Xiao-Min Liu, Dan Ke, Shao-Xian Hu, Cong Ye, Shu-Ling Han, Xiu-Yan Yang, Hao Li, Ci-Bo Huang, Ming Gao, Bei Lai, Yong-Jing Cheng, Xing-Fu Li, Li-Jun Song, Xiao-Xia Yu, Ai-Xue Wang, Li-Jun Wu, Yan-Hua Wang, Lan He, Wen-Wen Sun, Lu Gong, Xiao-Yuan Wang, Yi Wang, Yi Zhao, Xiao-Xia Li, Yan Wang, Yan Zhang, Yin Su, Chun-Fang Zhang, Rong Mu, Zhan-Guo Li.   

Abstract

The aim of this study is to investigate the remission rate of rheumatoid arthritis (RA) in China and identify its potential determinants. A multi-center cross-sectional study was conducted from July 2009 to January 2012. Data were collected by face-to-face interviews of the rheumatology outpatients in 28 tertiary hospitals in China. The remission rates were calculated in 486 RA patients according to different definitions of remission: the Disease Activity Score in 28 joints (DAS28), the Simplified Disease Activity Index (SDAI), the Clinical Disease Activity Index (CDAI), and the American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Boolean definition. Potential determinants of RA remission were assessed by univariate and multivariate analyses. The remission rates of RA from this multi-center cohort were 8.6% (DAS28), 8.4% (SDAI), 8.2% (CDAI), and 6.8% (Boolean), respectively. Favorable factors associated with remission were: low Health Assessment Questionnaire (HAQ) score, absence of rheumatoid factor (RF) and anti-cyclic citrullinated peptide (anti-CCP), and treatment of methotrexate (MTX) and hydroxychloroquine (HCQ). Younger age was also predictive for the DAS28 and the Boolean remission. Multivariate analyses revealed a low HAQ score, the absence of anti-CCP, and the treatment with HCQ as independent determinants of remission. The clinical remission rate of RA patients was low in China. A low HAQ score, the absence of anti-CCP, and HCQ were significant independent determinants for RA remission.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25413735     DOI: 10.1007/s10067-014-2828-3

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  48 in total

1.  Changes in cotherapies after initiation of disease-modifying antirheumatic drug therapy in patients with rheumatoid arthritis.

Authors:  Vivian K Kawai; Carlos G Grijalva; Patrick G Arbogast; Jeffrey R Curtis; Daniel H Solomon; Elizabeth Delzell; Lang Chen; Rita Ouellet-Hellstrom; Lisa Herrinton; Liyan Liu; Edward F Mitchel; C Michael Stein; Marie R Griffin
Journal:  Arthritis Care Res (Hoboken)       Date:  2011-10       Impact factor: 4.794

2.  New remission criteria for RA: 'modern times' in rheumatology--not a silent film, rather a 3D movie.

Authors:  Lennart T H Jacobsson; Merete Lund Hetland
Journal:  Ann Rheum Dis       Date:  2011-03       Impact factor: 19.103

3.  Remission of rheumatoid arthritis in clinical practice: application of the American College of Rheumatology/European League Against Rheumatism 2011 remission criteria.

Authors:  Shadi H Shahouri; Kaleb Michaud; Ted R Mikuls; Liron Caplan; Timothy S Shaver; James D Anderson; David N Weidensaul; Ruth E Busch; Shirley Wang; Frederick Wolfe
Journal:  Arthritis Rheum       Date:  2011-11

4.  Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.

Authors:  K L Hyrich; K D Watson; A J Silman; D P M Symmons
Journal:  Rheumatology (Oxford)       Date:  2006-05-16       Impact factor: 7.580

5.  [A multicenter study of coronary artery disease and its risk factors in rheumatoid arthritis in China].

Authors:  Chun Li; Xiu-ru Wang; Yi-da Tang; Yuan An; Yun-shan Zhou; Shi-wei Guo; Xiao-ying Zhang; Tian-jiao Duan; Jia-Xin Zhu; Xiao-feng Li; Li-zhi Wang; Cai-hong Wang; Yong-fu Wang; Rong Yang; Guo-chun Wang; Xin Lu; Ping Zhu; Li-na Chen; Hong-tao Jin; Jin-ting Liu; Xiang-yuan Liu; Lin Sun; Hai-ying Chen; Ping Wei; Jun-xiang Wang; Liu-fu Cui; Rong Shu; Bai-lu Liu; Zhuo-li Zhang; Guang-tao Li; Zhen-bin Li; Jing Yang; Jun-fang Li; Bin Jia; Feng-xiao Zhang; Jie-mei Tao; Shu-ling Han; Jin-ying Lin; Mei-qiu Wei; Xiao-min Liu; Dan Ke; Shao-xian Hu; Cong Ye; Xiu-yan Yang; Hao Li; Ci-bo Huang; Ming Gao; Pei Lai; Xing-fu Li; Li-jun Song; Yi Wang; Xiao-yuan Wang; Rong Mu; Yin Su; Zhan-guo Li
Journal:  Beijing Da Xue Xue Bao Yi Xue Ban       Date:  2012-04-18

6.  Patient and rheumatologist perspectives on glucocorticoids: an exercise to improve the implementation of the European League Against Rheumatism (EULAR) recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases.

Authors:  M C van der Goes; J W G Jacobs; M Boers; T Andrews; M A M Blom-Bakkers; F Buttgereit; N Caeyers; E H Choy; M Cutolo; J A P Da Silva; L Guillevin; M Holland; J R Kirwan; J Rovensky; K G Saag; G Severijns; S Webber; R Westhovens; J W J Bijlsma
Journal:  Ann Rheum Dis       Date:  2009-09-17       Impact factor: 19.103

7.  Sustained drug-free remission in rheumatoid arthritis after DAS-driven or non-DAS-driven therapy: a comparison of two cohort studies.

Authors:  Diane van der Woude; Karen Visser; Naomi B Klarenbeek; H Karel Ronday; André J Peeters; Pit J S M Kerstens; Ben A C Dijkmans; Tom W J Huizinga; Annette H M van der Helm-van Mil; Cornelia F Allaart
Journal:  Rheumatology (Oxford)       Date:  2012-02-15       Impact factor: 7.580

8.  Disease Activity Score 28 (DAS28) using C-reactive protein underestimates disease activity and overestimates EULAR response criteria compared with DAS28 using erythrocyte sedimentation rate in a large observational cohort of rheumatoid arthritis patients in Japan.

Authors:  Toshihiro Matsui; Yoshiaki Kuga; Atsushi Kaneko; Jinju Nishino; Yoshito Eto; Noriyuki Chiba; Masayuki Yasuda; Koichiro Saisho; Kota Shimada; Shigeto Tohma
Journal:  Ann Rheum Dis       Date:  2007-03-16       Impact factor: 19.103

9.  Understanding why rheumatoid arthritis patient treatment preferences differ by race.

Authors:  Florina Constantinescu; Suzanne Goucher; Arthur Weinstein; Wally Smith; Liana Fraenkel
Journal:  Arthritis Rheum       Date:  2009-04-15

10.  Very early rheumatoid arthritis as a predictor of remission: a multicentre real life prospective study.

Authors:  Elisa Gremese; Fausto Salaffi; Silvia Laura Bosello; Alessandro Ciapetti; Francesca Bobbio-Pallavicini; Roberto Caporali; Gianfranco Ferraccioli
Journal:  Ann Rheum Dis       Date:  2012-07-13       Impact factor: 19.103

View more
  8 in total

1.  Pain-related comorbidities and medication absence as predictors of clinical remission in RA.

Authors:  D Vega-Morales; S A Loredo-Alanís; M A Garza-Elizondo
Journal:  Clin Rheumatol       Date:  2015-05-15       Impact factor: 2.980

Review 2.  A new look at rheumatology in China--opportunities and challenges.

Authors:  Zhan-Guo Li
Journal:  Nat Rev Rheumatol       Date:  2015-01-20       Impact factor: 20.543

Review 3.  Pharmacotherapy Pearls in Rheumatology for the Care of Older Adult Patients: Focus on Oral Disease-Modifying Antirheumatic Drugs and the Newest Small Molecule Inhibitors.

Authors:  Blas Y Betancourt; Ann Biehl; James D Katz; Ananta Subedi
Journal:  Rheum Dis Clin North Am       Date:  2018-06-12       Impact factor: 2.670

4.  The usage of biological DMARDs and clinical remission of rheumatoid arthritis in China: a real-world large scale study.

Authors:  Yuan An; Tian Liu; Dongyi He; Lijun Wu; Juan Li; Yi Liu; Liqi Bi; Bin Zhou; Changsong Lin; Lan He; Xiangyuan Liu; Xiaofeng Li; Niansheng Yang; Zhuoli Zhang; Hui Song; Wei Wei; Jing Liu; Yu Bi; Zhanguo Li
Journal:  Clin Rheumatol       Date:  2016-10-05       Impact factor: 2.980

5.  Efficacy and Safety of Tofacitinib in Chinese Patients with Rheumatoid Arthritis.

Authors:  Zhan-Guo Li; Yi Liu; Hu-Ji Xu; Zhi-Wei Chen; Chun-De Bao; Jie-Ruo Gu; Dong-Bao Zhao; Yuan An; Lie-Ju Hwang; Lisy Wang; Joel Kremer; Qi-Zhe Wu
Journal:  Chin Med J (Engl)       Date:  2018-11-20       Impact factor: 2.628

6.  The prevalence and types of discordance between physician perception and objective data from standardized measures of rheumatoid arthritis disease activity in real-world clinical practice in the US.

Authors:  Wenhui Wei; Emma Sullivan; Stuart Blackburn; Chieh-I Chen; James Piercy; Jeffrey R Curtis
Journal:  BMC Rheumatol       Date:  2019-07-04

7.  Salvianolic Acid B Suppresses Inflammatory Mediator Levels by Downregulating NF-κB in a Rat Model of Rheumatoid Arthritis.

Authors:  Zeng-Bing Xia; Yong-Jian Yuan; Qiang-Hua Zhang; Heng Li; Ji-Lin Dai; Ji-Kang Min
Journal:  Med Sci Monit       Date:  2018-04-25

8.  Long-term prognosis and quality of life in patients with early rheumatoid arthritis treated according to the 2015 ACR guideline (LELAND): protocol for a multicentre prospective observational study in Southern China.

Authors:  Jinjun Zhao; Taihe Zhan; Junqing Zhu; Meida Fan; Qin Huang; Hao Ren; Jing Wu; Qinghong Yu; Jingli Lin; Qingqing Ouyang; Shengli An; Min Yang
Journal:  BMJ Open       Date:  2018-11-15       Impact factor: 2.692

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.